Magnetic resonance imaging of focal liver lesions: Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient

Thomas J. Vogl; Renate Hammerstingl; Wolfram Schwarz; Sherko Kümmel; Petra K. Müller; Thomas Balzer; Melchior J. Lauten; Jörn O. Balzer; Martin G. Mack; Christine Schimpfky; Harald Schrem; Wolf O. Bechstein; Peter Neuhaus; Roland Felix

doi:10.1097/00004424-199611000-00004

Magnetic resonance imaging of focal liver lesions: Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient

Thomas J. Vogl^*, Renate Hammerstingl, Wolfram Schwarz, Sherko Kümmel, Petra K. Müller, Thomas Balzer, Melchior J. Lauten, Jörn O. Balzer, Martin G. Mack, Christine Schimpfky, Harald Schrem, Wolf O. Bechstein, Peter Neuhaus, Roland Felix

^*Corresponding author for this work

Clinic of Pediatric and Adolescent Medicine

82 Citations (Scopus)

Abstract

RATIONALE AND OBJECTIVES. The authors assess the efficacy of static and dynamic magnetic resonance (MR) imaging using the superparamagnetic iron oxide SHU-555A (Resovist®) versus standard dose of gadolinium (Gd)-DTPA in patients with focal liver lesions. METHODS. Magnetic resonance imaging was performed in 30 patients suffering from histopathologically verified malignant (n = 22) and benign (n = 8) liver lesions. T2-weighted conventional and fat-suppressed as well as T1-weighted sequences were used before, during, and after fast intravenous administration of Resovist (1 mL/minute) at three doses of 4, 8, and 16 μmol/kg body weight. One week before the Resovist- enhanced MR imaging study 20 patients underwent Gd-DTPA-enhanced MR imaging. RESULTS. Detection rate was improved for metastatic lesions revealing 36 lesions unenhanced versus 53 focal lesions using Resovist-enhanced MR imaging. Gadolinium-DTPA-enhanced scans showed no additional lesion versus unenhanced and Resovist-enhanced MR imaging. Static and dynamic imaging demonstrated no measurable percentage signal intensity loss (PSIL) using Resovist-enhanced MR imaging versus a percentage enhancement of 79.7% in Gd- DTPA enhanced scans. In the dynamic T2-weighted sequences, hepatocellular carcinoma nodules (n = 4) showed a rapid decrease in signal intensity starting at 44 seconds. Postinfusion of Resovist followed by a low, constant increase in signal intensity. Gadolinium-DTPA enhanced scans showed a percentage enhancement of 73.4 focal nodular hyperplasia (FNH) and hemangioma revealed a strong and early dose-dependent PSIL 44 to 60 seconds postinfusion with a prolonged signal loss for the FNH in the late study. Statistical evaluation revealed a statistically significant superiority of Resovist- enhanced MR imaging concerning the detection and delineation of focal liver lesions compared with unenhanced and Gd-DTPA enhanced scans (P < 0.05). CONCLUSIONS. The fast infusion of the new superparamagnetic contrast agent Resovist shows advantages for dynamic and static MR imaging of focal liver lesions.

Original language	English
Journal	Investigative Radiology
Volume	31
Issue number	11
Pages (from-to)	696-708
Number of pages	13
ISSN	0020-9996
DOIs	https://doi.org/10.1097/00004424-199611000-00004
Publication status	Published - 11.1996

Research Areas and Centers

Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/00004424-199611000-00004

Cite this

Vogl, T. J., Hammerstingl, R., Schwarz, W., Kümmel, S., Müller, P. K., Balzer, T., Lauten, M. J., Balzer, J. O., Mack, M. G., Schimpfky, C., Schrem, H., Bechstein, W. O., Neuhaus, P., & Felix, R. (1996). Magnetic resonance imaging of focal liver lesions: Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient. Investigative Radiology, 31(11), 696-708. https://doi.org/10.1097/00004424-199611000-00004

@article{8b1c1a5ae9eb416c8a6d50cbacdb2fa8,

title = "Magnetic resonance imaging of focal liver lesions: Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient",

abstract = "RATIONALE AND OBJECTIVES. The authors assess the efficacy of static and dynamic magnetic resonance (MR) imaging using the superparamagnetic iron oxide SHU-555A (Resovist{\textregistered}) versus standard dose of gadolinium (Gd)-DTPA in patients with focal liver lesions. METHODS. Magnetic resonance imaging was performed in 30 patients suffering from histopathologically verified malignant (n = 22) and benign (n = 8) liver lesions. T2-weighted conventional and fat-suppressed as well as T1-weighted sequences were used before, during, and after fast intravenous administration of Resovist (1 mL/minute) at three doses of 4, 8, and 16 μmol/kg body weight. One week before the Resovist- enhanced MR imaging study 20 patients underwent Gd-DTPA-enhanced MR imaging. RESULTS. Detection rate was improved for metastatic lesions revealing 36 lesions unenhanced versus 53 focal lesions using Resovist-enhanced MR imaging. Gadolinium-DTPA-enhanced scans showed no additional lesion versus unenhanced and Resovist-enhanced MR imaging. Static and dynamic imaging demonstrated no measurable percentage signal intensity loss (PSIL) using Resovist-enhanced MR imaging versus a percentage enhancement of 79.7% in Gd- DTPA enhanced scans. In the dynamic T2-weighted sequences, hepatocellular carcinoma nodules (n = 4) showed a rapid decrease in signal intensity starting at 44 seconds. Postinfusion of Resovist followed by a low, constant increase in signal intensity. Gadolinium-DTPA enhanced scans showed a percentage enhancement of 73.4 focal nodular hyperplasia (FNH) and hemangioma revealed a strong and early dose-dependent PSIL 44 to 60 seconds postinfusion with a prolonged signal loss for the FNH in the late study. Statistical evaluation revealed a statistically significant superiority of Resovist- enhanced MR imaging concerning the detection and delineation of focal liver lesions compared with unenhanced and Gd-DTPA enhanced scans (P < 0.05). CONCLUSIONS. The fast infusion of the new superparamagnetic contrast agent Resovist shows advantages for dynamic and static MR imaging of focal liver lesions.",

author = "Vogl, {Thomas J.} and Renate Hammerstingl and Wolfram Schwarz and Sherko K{\"u}mmel and M{\"u}ller, {Petra K.} and Thomas Balzer and Lauten, {Melchior J.} and Balzer, {J{\"o}rn O.} and Mack, {Martin G.} and Christine Schimpfky and Harald Schrem and Bechstein, {Wolf O.} and Peter Neuhaus and Roland Felix",

year = "1996",

month = nov,

doi = "10.1097/00004424-199611000-00004",

language = "English",

volume = "31",

pages = "696--708",

journal = "Investigative Radiology",

issn = "0020-9996",

number = "11",

}

Vogl, TJ, Hammerstingl, R, Schwarz, W, Kümmel, S, Müller, PK, Balzer, T, Lauten, MJ, Balzer, JO, Mack, MG, Schimpfky, C, Schrem, H, Bechstein, WO, Neuhaus, P & Felix, R 1996, 'Magnetic resonance imaging of focal liver lesions: Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient', Investigative Radiology, vol. 31, no. 11, pp. 696-708. https://doi.org/10.1097/00004424-199611000-00004

TY - JOUR

T1 - Magnetic resonance imaging of focal liver lesions: Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient

AU - Vogl, Thomas J.

AU - Hammerstingl, Renate

AU - Schwarz, Wolfram

AU - Kümmel, Sherko

AU - Müller, Petra K.

AU - Balzer, Thomas

AU - Lauten, Melchior J.

AU - Balzer, Jörn O.

AU - Mack, Martin G.

AU - Schimpfky, Christine

AU - Schrem, Harald

AU - Bechstein, Wolf O.

AU - Neuhaus, Peter

AU - Felix, Roland

PY - 1996/11

Y1 - 1996/11

N2 - RATIONALE AND OBJECTIVES. The authors assess the efficacy of static and dynamic magnetic resonance (MR) imaging using the superparamagnetic iron oxide SHU-555A (Resovist®) versus standard dose of gadolinium (Gd)-DTPA in patients with focal liver lesions. METHODS. Magnetic resonance imaging was performed in 30 patients suffering from histopathologically verified malignant (n = 22) and benign (n = 8) liver lesions. T2-weighted conventional and fat-suppressed as well as T1-weighted sequences were used before, during, and after fast intravenous administration of Resovist (1 mL/minute) at three doses of 4, 8, and 16 μmol/kg body weight. One week before the Resovist- enhanced MR imaging study 20 patients underwent Gd-DTPA-enhanced MR imaging. RESULTS. Detection rate was improved for metastatic lesions revealing 36 lesions unenhanced versus 53 focal lesions using Resovist-enhanced MR imaging. Gadolinium-DTPA-enhanced scans showed no additional lesion versus unenhanced and Resovist-enhanced MR imaging. Static and dynamic imaging demonstrated no measurable percentage signal intensity loss (PSIL) using Resovist-enhanced MR imaging versus a percentage enhancement of 79.7% in Gd- DTPA enhanced scans. In the dynamic T2-weighted sequences, hepatocellular carcinoma nodules (n = 4) showed a rapid decrease in signal intensity starting at 44 seconds. Postinfusion of Resovist followed by a low, constant increase in signal intensity. Gadolinium-DTPA enhanced scans showed a percentage enhancement of 73.4 focal nodular hyperplasia (FNH) and hemangioma revealed a strong and early dose-dependent PSIL 44 to 60 seconds postinfusion with a prolonged signal loss for the FNH in the late study. Statistical evaluation revealed a statistically significant superiority of Resovist- enhanced MR imaging concerning the detection and delineation of focal liver lesions compared with unenhanced and Gd-DTPA enhanced scans (P < 0.05). CONCLUSIONS. The fast infusion of the new superparamagnetic contrast agent Resovist shows advantages for dynamic and static MR imaging of focal liver lesions.

AB - RATIONALE AND OBJECTIVES. The authors assess the efficacy of static and dynamic magnetic resonance (MR) imaging using the superparamagnetic iron oxide SHU-555A (Resovist®) versus standard dose of gadolinium (Gd)-DTPA in patients with focal liver lesions. METHODS. Magnetic resonance imaging was performed in 30 patients suffering from histopathologically verified malignant (n = 22) and benign (n = 8) liver lesions. T2-weighted conventional and fat-suppressed as well as T1-weighted sequences were used before, during, and after fast intravenous administration of Resovist (1 mL/minute) at three doses of 4, 8, and 16 μmol/kg body weight. One week before the Resovist- enhanced MR imaging study 20 patients underwent Gd-DTPA-enhanced MR imaging. RESULTS. Detection rate was improved for metastatic lesions revealing 36 lesions unenhanced versus 53 focal lesions using Resovist-enhanced MR imaging. Gadolinium-DTPA-enhanced scans showed no additional lesion versus unenhanced and Resovist-enhanced MR imaging. Static and dynamic imaging demonstrated no measurable percentage signal intensity loss (PSIL) using Resovist-enhanced MR imaging versus a percentage enhancement of 79.7% in Gd- DTPA enhanced scans. In the dynamic T2-weighted sequences, hepatocellular carcinoma nodules (n = 4) showed a rapid decrease in signal intensity starting at 44 seconds. Postinfusion of Resovist followed by a low, constant increase in signal intensity. Gadolinium-DTPA enhanced scans showed a percentage enhancement of 73.4 focal nodular hyperplasia (FNH) and hemangioma revealed a strong and early dose-dependent PSIL 44 to 60 seconds postinfusion with a prolonged signal loss for the FNH in the late study. Statistical evaluation revealed a statistically significant superiority of Resovist- enhanced MR imaging concerning the detection and delineation of focal liver lesions compared with unenhanced and Gd-DTPA enhanced scans (P < 0.05). CONCLUSIONS. The fast infusion of the new superparamagnetic contrast agent Resovist shows advantages for dynamic and static MR imaging of focal liver lesions.

UR - http://www.scopus.com/inward/record.url?scp=10344235969&partnerID=8YFLogxK

U2 - 10.1097/00004424-199611000-00004

DO - 10.1097/00004424-199611000-00004

M3 - Journal articles

C2 - 8915751

AN - SCOPUS:10344235969

SN - 0020-9996

VL - 31

SP - 696

EP - 708

JO - Investigative Radiology

JF - Investigative Radiology

IS - 11

ER -

Magnetic resonance imaging of focal liver lesions: Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient

Abstract

Research Areas and Centers

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this